Investor Overview
reVision Therapeutics Inc. is a preclinical-stage pharmaceutical company pioneering ophthalmic therapies and dedicated to the repurposing, development, and commercialization of generally recognized as safe (GRAS) drugs directed against ophthalmic disease and disorders for the treatment of Stargardt disease, dry age-related macular degeneration, dry eye disease, and proliferative vitreoretinopathy. reVision's lead candidate REV-0100 functions by sequestering and removing the toxic lipid-bisretinoid, such as A2E. reVision's lead compound was awarded both Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) designation by the US Food and Drug Administration.
